Surmodics Croissance future

Future contrôle des critères 4/6

Surmodics devrait augmenter ses bénéfices et ses revenus de 101% et de 11.7% par an respectivement, tandis que le BPA devrait croître de croître de 101.5% par an.

Informations clés

101.0%

Taux de croissance des bénéfices

101.5%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.0%
Taux de croissance des recettes	11.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	07 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:SRDX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2026	160	2	27	N/A	2
9/30/2025	141	-6	15	N/A	3
9/30/2024	126	-12	-3	0	N/A
6/30/2024	121	-1	-6	-2	N/A
3/31/2024	143	14	23	26	N/A
12/31/2023	138	6	10	13	N/A
9/30/2023	133	-2	8	11	N/A
6/30/2023	131	-23	4	7	N/A
3/31/2023	103	-36	-26	-23	N/A
12/31/2022	102	-32	-25	-21	N/A
9/30/2022	100	-27	-21	-17	N/A
6/30/2022	98	-13	-19	-14	N/A
3/31/2022	97	-10	-13	-8	N/A
12/31/2021	106	2	8	13	N/A
9/30/2021	105	4	9	15	N/A
6/30/2021	104	2	11	16	N/A
3/31/2021	107	7	20	24	N/A
12/31/2020	95	1	6	11	N/A
9/30/2020	95	1	10	14	N/A
6/30/2020	103	8	20	25	N/A
3/31/2020	101	7	7	13	N/A
12/31/2019	100	6	6	13	N/A
9/30/2019	100	8	1	8	N/A
6/30/2019	92	2	-6	0	N/A
3/31/2019	90	-2	-11	3	N/A
12/31/2018	87	-2	13	28	N/A
9/30/2018	81	-4	20	34	N/A
6/30/2018	78	-2	N/A	36	N/A
3/31/2018	74	1	N/A	37	N/A
12/31/2017	72	0	N/A	13	N/A
9/30/2017	73	4	N/A	14	N/A
6/30/2017	71	6	N/A	14	N/A
3/31/2017	73	9	N/A	20	N/A
12/31/2016	73	10	N/A	21	N/A
9/30/2016	71	10	N/A	25	N/A
6/30/2016	71	9	N/A	22	N/A
3/31/2016	67	9	N/A	18	N/A
12/31/2015	64	11	N/A	16	N/A
9/30/2015	62	12	N/A	15	N/A
6/30/2015	60	13	N/A	18	N/A
3/31/2015	59	13	N/A	19	N/A
12/31/2014	58	12	N/A	19	N/A
9/30/2014	57	12	N/A	18	N/A
6/30/2014	56	13	N/A	18	N/A
3/31/2014	56	13	N/A	17	N/A
12/31/2013	56	14	N/A	16	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: SRDX devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: SRDX devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: SRDX devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SRDX ( 11.7% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SRDX ( 11.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de SRDX devrait être élevé dans 3 ans

Surmodics Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 26% to US$43.00

Surmodics, Inc. Suspends Earnings Guidance for the Fiscal 2024

Price target decreased by 10% to US$52.33

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Recent updates

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 26% to US$43.00

Insufficient new directors

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce Thrombectomy System

Surmodics Receives FDA 510(k) Clearance for Pounce XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

Surmodics, Inc. Suspends Earnings Guidance for the Fiscal 2024

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Price target decreased by 10% to US$52.33

GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. (NasdaqGS:SRDX) for approximately $620 million.

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 24%

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024

New major risk - Revenue and earnings growth

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Surmodics, Inc., Annual General Meeting, Feb 08, 2024

Insider exercised options and sold US$107k worth of stock

Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15

Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$59.50

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q3, 2023 Results on Aug 02, 2023

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc.(NasdaqGS:SRDX) dropped from Russell 2000 Growth-Defensive Index

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Consensus revenue estimates increase by 11%

Surmodics, Inc. Receives FDA Approval for the SurVeil Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce LP Thrombectomy System

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Consensus EPS estimates upgraded to US$2.14 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics, Inc. to Report Q1, 2023 Results on Feb 06, 2023

Consensus EPS estimates fall by 20%

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon

Price target decreased to US$61.00

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options and sold US$64k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Surmodics, Inc. Announces 24-Month Data from Its Transcend Clinical Trial At the Vascular InterVentional Advances

Surmodics, Inc. to Report Q4, 2022 Results on Nov 09, 2022

Surmodics, Inc. Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

Surmodics gets additional $125M in credit facility

Surmodics, Inc. Announces 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surmodics, Inc. Updates Earnings Guidance for the Fiscal Year 2022

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M